Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 for the treatment of gastric cancer. It has a clinical collaboration agreement with Taiho Oncology, Inc. for the development of Oncoral in combination with LONSURF. Ascelia Pharma AB (publ) was founded in 2000 and is headquartered in Malmö, Sweden. Show More...
-
Website https://www.ascelia.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 4.13 SEK
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-06 2011-06 2012-06 2013-06 2014-06 2015-06 2016-06 2017-06 2018-06 2019-06 TTM Earnings Per Share SEK -2.12 -2.16 -3.11 Dividends SEK Payout Ratio % * Shares Mil 23.0 17.0 22.0 Book Value Per Share * SEK 9.41 Free Cash Flow Per Share * SEK Return on Assets % -24.82 -18.4 -37.13 Financial Leverage (Average) 1.04 1.04 1.07 Return on Equity % -25.77 -19.15 -39.07 Return on Invested Capital % -25.76 -19.16 -37.22 Interest Coverage -13.15 Current Ratio 13.37 20.54 12.92 Quick Ratio 12.47 20.3 12.83 Debt/Equity 0.010